TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7266894

Group type: EXPERIMENTAL
Intervention: E.N.L. protocol (erythromycin + neomycin + 600 mg lincomycin 1 hr prior to surgery)
Number of subjects: 30

Group type: COMPARATOR
Intervention: E.N. protocol (erythromycin + neomycin)
Number of subjects: 30
Study: 31552526

Group type: EXPERIMENTAL
Intervention: Omalizumab (150 mg) administered as a single subcutaneous injection 2 weeks postoperatively.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intranasal steroids (budesonide or mometasone furoate, 100 μg twice daily for 6 months) starting 2 weeks postoperatively.
Number of subjects: 20
Study: 31418855

Group type: EXPERIMENTAL
Intervention: 25 milligrams cobalt intravenously as CoCl2 weekly
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 50 milligrams cobalt intravenously as CoCl2 weekly
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 25 milligrams cobalt intravenously mid‐week and at the end of the week
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no cobalt administration)
Number of subjects: 8
Study: 28560832

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) targeted to weight loss
Number of subjects: 264

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE) control group
Number of subjects: 264
Study: 26082975

Group type: EXPERIMENTAL
Intervention: Albu‐BChE (50, 100, and 300 mg)
Number of subjects: 0
Study: 22948317

Group type: EXPERIMENTAL
Intervention: Prophylactic cholecystectomy (PC)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard surgery (SS)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Prophylactic cholecystectomy (PC) and Standard surgery (SS)
Number of subjects: 130
Study: 22018363

Group type: EXPERIMENTAL
Intervention: Akreos Adapt Advanced Optics aspheric intraocular lens (IOL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sensar AR40e spherical acrylic IOL
Number of subjects: 40
Study: 19455132

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 230
Study: 16756038

Group type: EXPERIMENTAL
Intervention: Intracutaneous injections of 0.1 mL sterile water (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isotonic saline as placebo (n = 25)
Number of subjects: 50
Study: 15116817

Group type: EXPERIMENTAL
Intervention: Laparoscopic (total extraperitoneal approach, TEP)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Shouldice technique
Number of subjects: 261
Study: 10780760

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone dipropionate (1.5 mg daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 9112304

Group type: EXPERIMENTAL
Intervention: roxithromycin
Number of subjects: 79

Group type: COMPARATOR
Intervention: erythromycin
Number of subjects: 79
Study: 7693425

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy consisting of fluorouracil, epirubicin plus cyclophosphamide (FEC) for 6 cycles
Number of subjects: 176

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 176
Study: 3513079

Group type: EXPERIMENTAL
Intervention: Balanced Salt Solution (BSS)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: BSS-Plus
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (contralateral eye)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Aphakic and lensectomy eyes
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: BSS and BSS-Plus
Number of subjects: 71
Study: 31927162

Group type: EXPERIMENTAL
Intervention: Relaxation Training plus Substance‐Education/12‐Steps (RT/SET)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Motivational Interviewing plus Cognitive Behavior Therapy (MI/CBT)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 199
Study: 30195996

Group type: COMPARATOR
Intervention: Intermittent sulfadoxine‐pyrimethamine (two doses of 1500 mg sulfadoxine and 75 mg pyrimethamine, 4 weeks apart)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Intermittent chloroquine (two doses of 600 mg on day 1, 600 mg on day 2, and 300 mg on day 3)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis (600 mg on day 1 then 300 mg every week)
Number of subjects: 900
Study: 27876265

Group type: EXPERIMENTAL
Intervention: Quadrupled hamstring tendon (HT) allograft
Number of subjects: 98

Group type: COMPARATOR
Intervention: Doubled tibialis anterior (TA) allograft
Number of subjects: 98
Study: 26276501

Group type: EXPERIMENTAL
Intervention: 0.5 mg HDC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.0 mg HDC
Number of subjects: 20
Study: 23855761

Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 21442611

Group type: EXPERIMENTAL
Intervention: LOTUS™
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Harmonic Ace®
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LigaSure™
Number of subjects: 18
Study: 19250365

Group type: EXPERIMENTAL
Intervention: Questionnaire responses from nulliparae who declined RCT participation
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Questionnaire responses regarding autonomy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Influence of midwife information
Number of subjects: 107
Study: 16962881

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg per day
Number of subjects: 5584

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg per day
Number of subjects: 5584

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg and 80 mg (combined analysis)
Number of subjects: 5584
Study: 15290426

Group type: EXPERIMENTAL
Intervention: Calf compression device
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plantar-calf sequential compression device
Number of subjects: 10
Study: 11426356

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (n = 18)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Patient-controlled analgesia with intravenous morphine (n = 15)
Number of subjects: 33
Study: 9429042

Group type: EXPERIMENTAL
Intervention: PRBC units transfused to survivors (median age 17 days, range 5-35)
Number of subjects: 31

Group type: COMPARATOR
Intervention: PRBC units transfused to nonsurvivors (median age 25 days, range 9-36)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Correlation of PRBC age with mortality
Number of subjects: 31
Study: 7868100

Group type: EXPERIMENTAL
Intervention: Postpartum monitoring plus medication (either previously effective medication or nortriptyline)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Monitoring alone
Number of subjects: 23
Study: 2508567

Group type: EXPERIMENTAL
Intervention: Regimen C: MMC 12 mg/m2 i.v. at operation day and 6 mg/m2 in every 2 months + UFT 600 mg/day p.o.
Number of subjects: 1138

Group type: COMPARATOR
Intervention: Regimen D: MMC 12 mg/m2 i.v. at operation day and 6 mg/m2 in every 2 months + UFT 400 mg/day p.o.
Number of subjects: 1138
Study: 789082

Group type: EXPERIMENTAL
Intervention: Propranolol (up to 480 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol (up to 600 mg daily)
Number of subjects: 0
Study: 31701363

Group type: EXPERIMENTAL
Intervention: Keratoconus
Number of subjects: 2002

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 2002
Study: 31264764

Group type: EXPERIMENTAL
Intervention: Insulin glargine (LY2963016)
Number of subjects: 1249
Study: 28744883

Group type: EXPERIMENTAL
Intervention: Doubly robust estimator
Number of subjects: 0
Study: 25205142

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1450

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1450
Study: 24133024

Group type: EXPERIMENTAL
Intervention: Thermal massager
Number of subjects: 95

Group type: COMPARATOR
Intervention: Artificial tears (0.1% sodium hyaluronate solution, five times daily)
Number of subjects: 95
Study: 22250936

Group type: EXPERIMENTAL
Intervention: Donor Luncheon with family present
Number of subjects: 0

Group type: COMPARATOR
Intervention: Luncheon with no donor family present
Number of subjects: 0
Study: 20737130

Group type: EXPERIMENTAL
Intervention: Long-pulsed diode laser with SHR (Super Hair Removal) mode
Number of subjects: 18

Group type: COMPARATOR
Intervention: Long-pulsed alexandrite laser
Number of subjects: 18
Study: 19075085

Group type: EXPERIMENTAL
Intervention: Support from media
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Personal support
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Community support
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Health care team support
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Workplace support
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Family and friends support
Number of subjects: 58
Study: 16116055

Group type: EXPERIMENTAL
Intervention: Nicorandil (12 mg intravenously before reperfusion)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo (intravenously before reperfusion)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study: 14598999

Group type: EXPERIMENTAL
Intervention: Early Risers 'Skills for Success' Program (CORE + FLEX)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Early Risers 'Skills for Success' Program (CORE + FLEX and CORE-only combined)
Number of subjects: 327

Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 327
Study: 10804076

Group type: EXPERIMENTAL
Intervention: Regular doses of nortriptyline (60 mg-80 mg/day)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Low doses of nortriptyline (10 mg-13 mg/day)
Number of subjects: 69
Study: 8960488

Group type: EXPERIMENTAL
Intervention: Polishing teeth
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Intraligamental injection
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Rubber dam placement
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Matrix band with wedge placement
Number of subjects: 735

Group type: COMPARATOR
Intervention: Toothbrushing alone
Number of subjects: 735
Study: 8507417

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (160 mg trimethoprim and 800 mg sulphamethoxazole) twice a day on Mondays, Wednesdays and Fridays (n = 81)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Dapsone (100 mg) plus pyrimethamine (25 mg) once a week (n = 85)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (TMP-SMX)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Dapsone plus pyrimethamine (DP)
Number of subjects: 166
Study: 3541819

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bromocriptine mesylate
Number of subjects: 0
Study: 28731885

Group type: EXPERIMENTAL
Intervention: Sleeper stretch daily for 8 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual activities
Number of subjects: 37
Study: 27265816

Group type: EXPERIMENTAL
Intervention: Nordic walking (six-week supervised group training once per week, followed by six weeks of independent Nordic walking 4 times a week for 30 minutes each session)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 40
Study: 24403477

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg of elemental zinc/day for eight weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 21383341

Group type: EXPERIMENTAL
Intervention: Effervescent ibuprofen (400 mg)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Standard ibuprofen (Nurofen(®) 2 × 200 mg)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 20730396

Group type: EXPERIMENTAL
Intervention: HeartWave500 (HW)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard transtelephonic (TT) event recorder
Number of subjects: 120
Study: 18427840

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 16171715

Group type: EXPERIMENTAL
Intervention: 8-frame GBPS
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 16-frame GBPS
Number of subjects: 65
Study: 12576370

Group type: EXPERIMENTAL
Intervention: Inhalation of epinephrine, 1.5 mg, in 4 mL of 3% saline solution (group 2; n = 27)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Inhalation of epinephrine, 1.5 mg, in 4 mL of 0.9% saline solution (group 1; n = 25)
Number of subjects: 52
Study: 10389751

Group type: EXPERIMENTAL
Intervention: Oral contraceptive use
Number of subjects: 2116

Group type: COMPARATOR
Intervention: Screened and control arms of the NBSS
Number of subjects: 2116
Study: 8594240

Group type: EXPERIMENTAL
Intervention: Zidovudine therapy during pregnancy and/or during labor and delivery
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Zidovudine therapy during gestation
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 92
Study: 8487326

Group type: COMPARATOR
Intervention: Methotrexate (60 mg/m2) and Fluorouracil (600 mg/m2) (MF)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (100 mg/m2) orally on days 1‐14 plus MF (CMF)
Number of subjects: 255
Study: 3031714

Group type: EXPERIMENTAL
Intervention: 0.4 mg ACTH 4-10
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29673306

Group type: EXPERIMENTAL
Intervention: Date SMART program
Number of subjects: 109

Group type: COMPARATOR
Intervention: Knowledge Only (KO) comparison
Number of subjects: 109
Study: 29607843

Group type: EXPERIMENTAL
Intervention: Bi‐directional spiral
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lentulo spiral
Number of subjects: 34

Group type: COMPARATOR
Intervention: Incremental technique
Number of subjects: 34

Group type: COMPARATOR
Intervention: Past inject
Number of subjects: 34
Study: 27680029

Group type: EXPERIMENTAL
Intervention: Intrauterine 500 IU hCG in up to 0.5 ml normal saline
Number of subjects: 158

Group type: COMPARATOR
Intervention: Intrauterine 0.5 ml normal saline
Number of subjects: 158
Study: 24913343

Group type: EXPERIMENTAL
Intervention: Collaborative stepped care
Number of subjects: 180

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 180
Study: 22387758

Group type: EXPERIMENTAL
Intervention: Easy task condition with 3 letters (positive probes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demanding task condition with 5 letters (probe items)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High memory load condition
Number of subjects: 0
Study: 20136765

Group type: EXPERIMENTAL
Intervention: Football training (FG; n=19)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Running training (RG; n=18)
Number of subjects: 37
Study: 18217157

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose (LD) / 10 mg maintenance dose (MD)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Clopidogrel 300 mg LD / 75 mg MD
Number of subjects: 41

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg LD / 75 mg MD
Number of subjects: 41
Study: 15452187

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 U subcutaneous weekly for 16 weeks
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Nonresponders (irrespective of treatment arm)
Number of subjects: 344
Study: 12854748

Group type: EXPERIMENTAL
Intervention: Unilateral posteroventral pallidotomy (PVP) - left side
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Unilateral posteroventral pallidotomy (PVP) - right side
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Unilateral posteroventral pallidotomy (PVP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waitlist control group (no surgery)
Number of subjects: 36
Study: 10811451

Group type: EXPERIMENTAL
Intervention: 131I-MAb-LL2 administered in a twice weekly pattern with 20 mg of unlabeled LL2 prior to each dose
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 131I-MAb-LL2
Number of subjects: 21
Study: 8897877

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron (5‐HT3 antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1808368

Group type: EXPERIMENTAL
Intervention: External-Self Dual Reinforcement (ESR)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Discontinuation of Self Reinforcement after External-Self Dual Reinforcement (delta SR)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Discontinuation of External Reinforcement following Dual Reinforcement (delta ER)
Number of subjects: 132

Group type: COMPARATOR
Intervention: External Reinforcement (ER)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Discontinuation of External-Self Dual Reinforcement (delta ESR)
Number of subjects: 132
Study: 6800270

Group type: EXPERIMENTAL
Intervention: Amitriptyline tapering and discontinuation (double-blind)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Amitriptyline tapering and discontinuation
Number of subjects: 17
Study: 31917714

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation present
Number of subjects: 3845
Study: 31351660

Group type: EXPERIMENTAL
Intervention: Cligosiban 400 mg
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Cligosiban 800 mg
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Cligosiban 1200 mg
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 28204722

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg, titrated intravenously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine (10 mg additional)
Number of subjects: 0
Study: 25691036

Group type: EXPERIMENTAL
Intervention: Deferasirox treatment for 1 year
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Baseline LPI
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Transferrin saturation (TfSat)
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Serum ferritin (SF)
Number of subjects: 1530
Study: 25346838

Group type: EXPERIMENTAL
Intervention: High-volume evacuator
Number of subjects: 0

Group type: COMPARATOR
Intervention: No high-volume evacuator
Number of subjects: 0
Study: 22027216

Group type: EXPERIMENTAL
Intervention: Isolated hip abductor and external rotator strengthening (3 times per week for 8 weeks)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Isolated hip abductor and external rotator strengthening (exercise group)
Number of subjects: 28
Study: 19460396

Group type: EXPERIMENTAL
Intervention: Letter identification task with pairs of adjacent letters presented at varying distances from fixation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model of encoded position of each letter as independent and Gaussian distributed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letter size variation in the task.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of a pre-cue in the task.
Number of subjects: 0
Study: 17502630

Group type: EXPERIMENTAL
Intervention: Ultrasonography screening for AAA
Number of subjects: 67770
Study: 15345157

Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate (Dermabond)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Absorbable suture (3/0 polydiaxanone)
Number of subjects: 25
Study: 11475442

Group type: EXPERIMENTAL
Intervention: IFN-beta-1a 30 mcg
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: IFN-beta-1a 60 mcg
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: MRI with and without gadolinium-enhancement
Number of subjects: 802
Study: 9440756

Group type: EXPERIMENTAL
Intervention: Intensive-course 5-FU plus leucovorin plus levamisole for 6 months
Number of subjects: 891

Group type: COMPARATOR
Intervention: Standard 5-FU plus levamisole for 6 months
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Intensive-course 5-FU plus leucovorin plus levamisole for 12 months
Number of subjects: 891

Group type: COMPARATOR
Intervention: Standard 5-FU plus levamisole for 12 months
Number of subjects: 891
Study: 7989637

Group type: EXPERIMENTAL
Intervention: 10 mg MIF‐1 (Pro‐Leu‐Gly‐NH2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study: 2465562

Group type: EXPERIMENTAL
Intervention: Histaglobin-Triplex (combination of histamine and human gammaglobulin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (human gammaglobulins without histamine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Histaglobin-Triplex
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 47281

Group type: EXPERIMENTAL
Intervention: Indoprofen 100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Indoprofen 200 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aspirin 600 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aspirin 1000 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30508293

Group type: EXPERIMENTAL
Intervention: 500 mL water drink
Number of subjects: 8300

Group type: EXPERIMENTAL
Intervention: 330 mL water drink
Number of subjects: 8300

Group type: COMPARATOR
Intervention: Placebo intervention (pre-donation arm exercise)
Number of subjects: 8300

Group type: COMPARATOR
Intervention: Standard care controls
Number of subjects: 8300
Study: 28051800

Group type: EXPERIMENTAL
Intervention: Rifaximin (1,200 mg/day)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Lactulose (30-120 mL/day)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 112
Study: 26030318

Group type: EXPERIMENTAL
Intervention: Interpersonal and social rhythm therapy (IPSRT)
Number of subjects: 17
Study: 24184427

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 62
Study: 21870174

Group type: EXPERIMENTAL
Intervention: Healthy Diet
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Whole-grain-enriched diet (WGED)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 131
Study: 18469253

Group type: EXPERIMENTAL
Intervention: Fiber-poor FVJ
Number of subjects: 4358

Group type: EXPERIMENTAL
Intervention: Fruits, vitamin C-rich FVJ, FVJ ascorbic acid, and fiber-poor FVJ categories
Number of subjects: 4358